Natural born killers - how the body's frontline immune cells decide which cells to destroy
28 July 2009
The mechanism used by ‘Natural Killer’ immune cells in the human body to distinguish between diseased cells, which they are meant to destroy, and normal cells, which they are meant to leave alone, is revealed in new detail in research published today in PLoS Biology.
Understanding how this aspect of the body’s natural defences works could help medical researchers develop new ways of boosting these defences to treat disease.
The research was funded primarily by the Lister Institute for Preventative Medicine and the Medical Research Council, with additional support from the Biotechnology and Biological Sciences Research Council, the Royal Society and the Wellcome Trust.
Natural Killer (NK) cells – a type of white blood cell - are a major component of the human body’s innate immune system. Over 1,000 NK cells are found in every drop of blood. They provide a fast frontline defence against tumours, viruses and bacterial infections, by latching onto and killing cells in the human body that are cancerous or are infected with a virus or a bacterial pathogen.
On their journey round the human body NK cells regularly latch onto normal non-diseased cells too, before moving off, leaving them unharmed. Previously, the process by which NK cells made the right decision to kill or not kill another cell was unclear.
Now, a team of researchers from Imperial College London have used high speed microscopy imaging techniques to observe the NK cell decision making process in action. This has revealed striking differences in the behaviour of NK cells when interacting with healthy or diseased cells.
The outcome of the decision making process is determined by how receptors on the surface of the NK cell interact with proteins on the surface of the captured cell. Every NK cell has two types of surface receptors – activators, which turn the killing mechanism ‘on’ and inhibitors which turn the killing mechanism ‘off’.
Professor Davis and his colleagues discovered that if a captured cell is diseased or cancerous, it interacts with a large number of the NK cell’s activator receptors, which makes the NK cell stop dead in its tracks and spread out over the captured cell. During this spreading process the NK cell continuously reads the ‘on’ and ‘off’ signals from its surface contact with the captured cell. If the ‘on’ signals dominate, the NK cell remains in contact with the captured cell for a long time and eventually kills it.
Conversely if the captured cell is healthy, it interacts with more of the NK cell’s inhibitors – and fewer of its activators – meaning that the ‘off’ signals dominate and the ‘stopping and spreading’ process doesn’t occur, allowing the NK cell to quickly move off in search of a new target.
Principal investigator of the new study, Professor Dan Davis from Imperial College London’s Department of Life Sciences, explains: "Scientists have known for a long time that the proteins on the surface on Natural Killer cells are involved in answering the ‘to kill or not to kill?’ question, but we’ve not known exactly how these molecular cues are translated into the correct response. Our research has shown that information gleaned from its surface receptors tells the Natural Killer cell whether to stop patrolling and commence killing, or to move off quickly, and harmlessly, in search of another target."
Dr Fiona Culley, lead author of the study from the National Heart and Lung Institute at Imperial, says that finding out how NK cells use this process to sift out diseased cells from normal ones paints the clearest picture to date of how these cells do their vital work: "Considering that NK cells play such an important part in our immune response to cancer and disease, relatively little is known about their functionality – how exactly they work and how they interact with the cells they encounter inside us. This study adds significantly to our understanding of how Natural Killer cells distinguish between healthy and diseased cells."
Notes to editors
‘Natural Killer Cell Signal Integration Balances Synapse Symmetry and Migration’, PLoS Biology, Tuesday 28 July 2009.
Fiona J. Culley(1), Matthew Johnson(1), J. Henry Evans(1), Sunil Kumar(1), Rupert Crilly(1), Juan Casasbuenas(1), Tim Schnyder(1), Maryam Mehrabi(1), Mahendra P. Deonarain(1), Dmitry S. Ushakov(2), Veronique Braud(3), Gunter Roth(4), Roland Brock(5), Karsten Kohler(1), Daniel M. Davis(1).
- Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
- Institut de Pharmacologie Moleculaire et Cellulaire, Centre National de la Recherche Scientifique/Universite de Nice-Sophia Antipolis, UMR6097, Valbonne, France
- Department of Molecular Biology, Interfacultary Institute for Cell Biology, University of Tubingen, Tubingen, Germany
- Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
About About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 13,000 students and 6,000 staff of the highest international quality.
Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve health in the UK and globally, tackle climate change and develop clean and sustainable sources of energy.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £450M in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors. BBSRC carries out its mission by funding internationally competitive research, providing training in the biosciences, fostering opportunities for knowledge transfer and innovation and promoting interaction with the public and other stakeholders on issues of scientific interest in universities, centres and institutes.
The Babraham Institute, Institute for Animal Health, Institute of Food Research, John Innes Centre and Rothamsted Research are Institutes of BBSRC. The Institutes conduct long-term, mission-oriented research using specialist facilities. They have strong interactions with industry, Government departments and other end-users of their research.
Matt Goode, Head of External Relations
tel: 01793 413299
Tracey Jewitt, Media Officer
tel: 01793 414694
fax: 01793 413382